Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer

Study ID
NCT02619435

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

STREAM

Trial Summary

The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.

More informations

Trial Starting Date

Nov 30,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age 70 Years

Enrollement Limit